fluoxetine (Q422244)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

chemical compound

Sprache	Label	Description	Also known as
Englisch	fluoxetine	chemical compound

Statements

group of stereoisomers

0 references

chemical compound

0 references

response to fluoxetine

subject has role

1 reference

Gene Ontology release 2019-11-16

cellular response to fluoxetine

subject has role

1 reference

Gene Ontology release 2019-11-16

0 references

chemical structure

Fluoxetine-2D-skeletal.svg
524 × 263; 13 KB

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=122951750

309.134049 dalton

1 reference

language of work or name

fluoxetine (English)

3 October 2016

discoverer or inventor

0 references

chemical formula

C₁₇H₁₈F₃NO

1 reference

language of work or name

fluoxetine (English)

19 November 2016

canonical SMILES

CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F

1 reference

language of work or name

fluoxetine (English)

19 November 2016

defined daily dose

20 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N06AB03

active ingredient in

1 reference

14 February 2018

1 reference

14 February 2018

0 references

0 references

0 references

World Health Organisation international non-proprietary name

fluoxetine (English)

1 reference

language of work or name

Fluoxetine (English)

19 January 2016

Hordeum vulgare

1 reference

Release of gramine from the surface of barley leaves

medical condition treated

1 reference

language of work or name

13 December 2016

bulimia nervosa

1 reference

language of work or name

13 December 2016

neurotic disorder

1 reference

language of work or name

13 December 2016

obsessive-compulsive disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

mental disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

post-traumatic stress disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

anxiety disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

intention tremor

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 2B

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Potassium inwardly-rectifying channel, subfamily J, member 6

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Solute carrier family 29 member 4

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

solute carrier family 6 member 4

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

route of administration

oral administration

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=122951750

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Fluoxetine

2 February 2018

subject has role

selective serotonin reuptake inhibitor

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

cytochrome P-450 CYP2D6 inhibitors

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

second-generation antidepressive agents

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

0.11±0.01 United States dollar

2 references

http://www.walgreens.com/images/psc/VPG_List_Update_01-02-2015.pdf#$10/90-day

http://i.walmart.com/i/if/hmp/fusion/four_dollar_drug_list.pdf#$10/90-day

FLUoxetine

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

PROzac

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

0 references

0 references

0 references

1 reference

imported from Wikimedia project

English Wikipedia

Wikimedia import URL

https://en.wikipedia.org/w/index.php?title=Fluoxetine&oldid=950427591

Commons category

Fluoxetine

0 references

Identifiers

Bibliothèque nationale de France ID

subject named as

Fluoxétine

1 reference

Nuovo soggettario

https://thes.bncf.firenze.sbn.it/termine.php?id=6679

13 June 2021

National Library of Israel J9U ID

987007539315005171

1 reference

National Library of Israel

Library of Congress authority ID

subject named as

Fluoxetine

1 reference

Nuovo soggettario

https://thes.bncf.firenze.sbn.it/termine.php?id=6679

13 June 2021

InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3

1 reference

language of work or name

fluoxetine (English)

19 November 2016

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

1 reference

language of work or name

fluoxetine (English)

19 November 2016

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

fluoxetine (English)

19 November 2016

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

CAS Common Chemistry

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=54910-89-3

1 reference

language of work or name

Fluoxetine (English)

19 November 2016

2 references

language of work or name

fluoxetine (English)

19 November 2016

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

Reaxys registry number

39914106

0 references

mapping relation type

0 references

mapping relation type

1 reference

matched by identifier from

International Chemical Identifier

InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3

1 reference

language of work or name

FLUOXETINE (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU150901

0 references

MSBNK-Athens_Univ-AU150902

0 references

MSBNK-Athens_Univ-AU150903

0 references

MSBNK-Athens_Univ-AU150904

0 references

MSBNK-Athens_Univ-AU150905

0 references

MSBNK-Eawag-EA033401

0 references

MSBNK-Eawag-EA033402

0 references

MSBNK-Eawag-EA033407

0 references

MSBNK-Eawag-EA033408

0 references

MSBNK-Eawag-EA033412

0 references

MSBNK-Eawag-EA033413

0 references

MSBNK-Eawag-EA033414

0 references

MSBNK-Eawag_Additional_Specs-ET070001

0 references

MSBNK-Eawag_Additional_Specs-ET070002

0 references

MSBNK-Eawag_Additional_Specs-ET070003

0 references

MSBNK-Eawag_Additional_Specs-ET070004

0 references

MSBNK-Eawag_Additional_Specs-ET070005

0 references

MSBNK-Waters-WA001281

0 references

MSBNK-Waters-WA001282

0 references

MSBNK-Waters-WA001283

0 references

MSBNK-Waters-WA001284

0 references

MSBNK-Waters-WA001285

0 references

splash10-014i-0190000000-e9bcd2accdf5b7e40a88

0 references

splash10-014i-0590000000-04b1d4265cb156217f40

0 references

splash10-014i-0790000000-5c42b9a9a2cd0c4114aa

0 references

splash10-0gb9-0960000000-88822d2fb3e7c0cdc0b3

0 references

splash10-0002-0900000000-6b560941c92823b7901c

0 references

splash10-03di-0109000000-1531c1e1630dcb42b497

0 references

splash10-0006-9000000000-53199cfe3b343ae81afd

0 references

splash10-03di-0109000000-0e790a7e6032e51bfeb3

0 references

splash10-00kf-9800000000-64d39c4a4fcc7f8b6f47

0 references

splash10-00kf-9700000000-e516356ce3eca65bece8

0 references

splash10-0zgi-1390000000-84c6bc70aefcd3758f31

0 references

splash10-0f7o-6940000000-a424e26ecc7465229968

0 references

splash10-0a4m-0390000000-9b7253cd5718aa434e46

0 references

splash10-0a4m-0290000000-d88f8004205c7223aa9f

0 references

splash10-03di-0409000000-03f5678c6178e634f254

0 references

splash10-014l-4900000000-2940e7bc3f6a559e61fc

0 references

splash10-014l-5900000000-c904d50adb4d1ea90abd

0 references

splash10-014l-5900000000-5cbc74ddfe414085c9bd

0 references

splash10-0002-0900000000-f5f65bd85fe3483260bb

0 references

splash10-0006-9200000000-dcf68dbfd090c7fdfe11

0 references

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

0 references

611-209-7

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine (English)

CAS no.: 54910-89-3 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine (English)

CAS no.: 54910-89-3 (English)

1 reference

language of work or name

Fluoxetine (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

fluoxetine (English)

19 November 2016

MeSH descriptor ID

subject named as

Fluoxetine

0 references

D02.092.831.280

0 references

1 reference

Global Substance Registration System

language of work or name

fluoxetine (English)

19 November 2016

1 reference

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

fluoxetine (English)

19 November 2016

matched by identifier from

RTHCYVBBDHJXIQ-UHFFFAOYSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

fluoxetine (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

Fluoxetine (English)

19 January 2016

IEDB Epitope ID

1 reference

Immune Epitope Database and Analysis Resource

IEDB Epitope ID

1 September 2021

da42eb63-fafd-42b7-9ebb-099436a5a8f5

1 reference

BNCF Thesaurus ID

1 reference

Nuovo soggettario

0 references

electronic Essential Medicines List medicine ID

0 references

Encyclopædia Britannica Online ID

subject named as

Prozac

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Gran Enciclopèdia Catalana ID

0 references

Gran Enciclopèdia Catalana ID (former scheme)

0 references

FluoxetineHydrochloride

1 reference

9 July 2020

Microsoft Academic ID

0 references

New York Times topic ID

subject/prozac-drug

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Fluoxetine-Prozac

1 reference

0 references

Store norske leksikon ID

0 references

UK Parliament thesaurus ID

subject named as

Prozac

0 references

1 reference

Global Substance Registration System

language of work or name

fluoxetine (English)

19 November 2016

1 reference

based on heuristic

inferred by common MeSH mappings on source and on Wikidata

25 May 2023

WikiProjectMed ID

0 references

WordNet 3.1 Synset ID

03375773-n

1 reference

subject named as

fluoksetiini

fluoxetin

fluoxetine

1 reference

YSO-Wikidata mapping project

28 January 2022

Sitelinks

Wikipedia(48 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(1 entry)

itwikiquote Fluoxetina

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Fluoxetine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q422244&oldid=2236946492"